DELCATH SYSTEMS, INC.
About DELCATH SYSTEMS, INC.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $85.2M
- Net income
- $2.7M
- Total assets
- $123.6M
- Market cap
- $368.3M
- Gross margin
- 86.2%
- Operating margin
- 0.8%
- Net margin
- 3.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $85.2M
- Cost of revenue
- $11.8M
- Gross profit
- $73.4M
- Operating expenses
- $72.8M
- Operating income
- $660.0K
- Income tax
- $810.0K
- Net income
- $2.7M
- EPS (basic)
- $0.08
- EPS (diluted)
- $0.07
Balance sheet
- Total assets
- $123.6M
- Current assets
- $119.5M
- Total liabilities
- $12.4M
- Current liabilities
- $10.9M
- Shareholders’ equity
- $111.2M
Cash flow
- Operating cash flow
- $22.5M
- Investing cash flow
- -$26.6M
- Financing cash flow
- $15.0M
- Net cash flow
- $11.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $368.3M
- P/E ratio
- 156.3
- EPS (diluted)
- $0.07
- Shares outstanding
- 33.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 19, 2000
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $2.7M in FY2025.
- Revenue grew 2855% from FY2021 to FY2025.
- Gross margin of 86.2%, net margin 3.2%.
- Trading 40% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 156.3.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review DELCATH SYSTEMS, INC..
Write a review
News about DELCATH SYSTEMS, INC.
News & sentiment via Polygon.io
